HSBC Initiates Coverage On AbbVie with Buy Rating, Announces Price Target of $167
Portfolio Pulse from richadhand@benzinga.com
HSBC analyst Rajesh Kumar has initiated coverage on AbbVie (NYSE:ABBV) with a Buy rating and a price target of $167.
July 14, 2023 | 8:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HSBC has initiated coverage on AbbVie with a Buy rating and a price target of $167, which could positively impact the stock.
The Buy rating and high price target from HSBC indicate a positive outlook for AbbVie. This could lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100